BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 16107876)

  • 1. MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation.
    Wang C; Ivanov A; Chen L; Fredericks WJ; Seto E; Rauscher FJ; Chen J
    EMBO J; 2005 Sep; 24(18):3279-90. PubMed ID: 16107876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YY1 inhibits the activation of the p53 tumor suppressor in response to genotoxic stress.
    Grönroos E; Terentiev AA; Punga T; Ericsson J
    Proc Natl Acad Sci U S A; 2004 Aug; 101(33):12165-70. PubMed ID: 15295102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of p53 degradation by Mdm2 acetylation.
    Wang X; Taplick J; Geva N; Oren M
    FEBS Lett; 2004 Mar; 561(1-3):195-201. PubMed ID: 15013777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SMAR1 forms a ternary complex with p53-MDM2 and negatively regulates p53-mediated transcription.
    Pavithra L; Mukherjee S; Sreenath K; Kar S; Sakaguchi K; Roy S; Chattopadhyay S
    J Mol Biol; 2009 May; 388(4):691-702. PubMed ID: 19303885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation.
    Ito A; Kawaguchi Y; Lai CH; Kovacs JJ; Higashimoto Y; Appella E; Yao TP
    EMBO J; 2002 Nov; 21(22):6236-45. PubMed ID: 12426395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
    Ghosh M; Huang K; Berberich SJ
    Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of p53 and MDM2 activity by MTBP.
    Brady M; Vlatkovic N; Boyd MT
    Mol Cell Biol; 2005 Jan; 25(2):545-53. PubMed ID: 15632057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53.
    Honda R; Yasuda H
    EMBO J; 1999 Jan; 18(1):22-7. PubMed ID: 9878046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acidic domain is indispensable for MDM2 to negatively regulate the acetylation of p53.
    Wang Q; Yang Y; Wang L; Zhang PZ; Yu L
    Biochem Biophys Res Commun; 2008 Sep; 374(3):437-41. PubMed ID: 18638452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDM2 promotes ubiquitination and degradation of MDMX.
    Pan Y; Chen J
    Mol Cell Biol; 2003 Aug; 23(15):5113-21. PubMed ID: 12860999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation.
    Stommel JM; Wahl GM
    EMBO J; 2004 Apr; 23(7):1547-56. PubMed ID: 15029243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity.
    Xirodimas DP; Saville MK; Bourdon JC; Hay RT; Lane DP
    Cell; 2004 Jul; 118(1):83-97. PubMed ID: 15242646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KAP1 dictates p53 response induced by chemotherapeutic agents via Mdm2 interaction.
    Okamoto K; Kitabayashi I; Taya Y
    Biochem Biophys Res Commun; 2006 Dec; 351(1):216-22. PubMed ID: 17056014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation.
    Koumenis C; Alarcon R; Hammond E; Sutphin P; Hoffman W; Murphy M; Derr J; Taya Y; Lowe SW; Kastan M; Giaccia A
    Mol Cell Biol; 2001 Feb; 21(4):1297-310. PubMed ID: 11158315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The contribution of the acidic domain of MDM2 to p53 and MDM2 stability.
    Argentini M; Barboule N; Wasylyk B
    Oncogene; 2001 Mar; 20(11):1267-75. PubMed ID: 11313871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-terminal modifications regulate MDM2 dissociation and nuclear export of p53.
    Carter S; Bischof O; Dejean A; Vousden KH
    Nat Cell Biol; 2007 Apr; 9(4):428-35. PubMed ID: 17369817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2-ARF complex regulates p53 sumoylation.
    Chen L; Chen J
    Oncogene; 2003 Aug; 22(34):5348-57. PubMed ID: 12917636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53- and Mdm2-independent repression of NF-kappa B transactivation by the ARF tumor suppressor.
    Rocha S; Campbell KJ; Perkins ND
    Mol Cell; 2003 Jul; 12(1):15-25. PubMed ID: 12887889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase.
    Okamoto K; Taya Y; Nakagama H
    FEBS Lett; 2009 Sep; 583(17):2710-4. PubMed ID: 19619542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bivalent binding of p14ARF to MDM2 RING and acidic domains inhibits E3 ligase function.
    Kowalczyk D; Nakasone MA; Smith BO; Huang DT
    Life Sci Alliance; 2022 Aug; 5(12):. PubMed ID: 35944929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.